Halozyme Therapeutics, Inc.

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics is a biotech company that develops and commercializes ENHANZE, a proprietary drug-delivery technology based on recombinant human hyaluronidase PH20 that enables subcutaneous administration of biologics and small molecules. It partners with pharmaceutical firms to reformulate existing intravenous therapies, accelerating onset, reducing infusion times, and improving patient experience. The company supplies bulk rHuPH20 enzyme and licenses intellectual property for co-formulated products across oncology, immunology, and specialty therapeutics, generating revenue through royalties, milestone payments, and material sales.